Management of Long-COVID Postural Orthostatic Tachycardia Syndrome With Enhanced External Counterpulsation
Swathi Varanasi, Mohankrishnan Sathyamoorthy, Sanjayanth Chamakura, Sachin A Shah, Swathi Varanasi, Mohankrishnan Sathyamoorthy, Sanjayanth Chamakura, Sachin A Shah
Abstract
A growing number of patients diagnosed with COVID-19 disease have been reported to have postural orthostatic tachycardia syndrome (POTS) after the acute phase. A 57-year-old female was diagnosed with COVID-19 in December 2020. As a result of her acute illness, she was hospitalized for COVID pneumonia and respiratory failure, followed by stays at an acute care facility and home rehabilitation center. After the acute phase, the patient was diagnosed with long-COVID-19-associated POTS with symptoms such as fatigue, "brain fog," and dyspnea. The patient was referred to an enhanced external counterpulsation (EECP) treatment center and underwent 15, one-hour sessions over three weeks. Upon completion of therapy, the patient reported improvements with "brain fog" and the ability to perform activities of daily living. Her Patient-Reported Outcome Measurement Information System (PROMIS) Fatigue score was reduced by three points, six-minute walk distance increased by 85 feet, and Duke Activity Status Index (DASI) improved by over 15 points. EECP therapy was chosen due to the overlap in underlying pathology driving POTS and the mechanisms of action of EECP. This report is the first case of using EECP for the successful management of COVID-19-associated POTS and warrants further trials.
Keywords: covid long haul syndrome; eecp; long covid; pasc; postural orthostatic tachycardia syndrome.
Conflict of interest statement
The authors have declared financial relationships, which are detailed in the next section.
Copyright © 2021, Varanasi et al.
References
- Confronting our next national health disaster - long-haul Covid. Phillips S, Williams MA. N Engl J Med. 2021;385:577–579.
- More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, Villapol S. Sci Rep. 2021;11:16144.
- Long-haul post-COVID-19 symptoms presenting as a variant of postural orthostatic tachycardia syndrome: the Swedish experience. Johansson M, Ståhlberg M, Runold M, et al. JACC Case Rep. 2021;3:573–580.
- Postural orthostatic tachycardia syndrome (POTS) and other autonomic disorders after COVID-19 infection: a case series of 20 patients. Blitshteyn S, Whitelaw S. Immunol Res. 2021;69:205–211.
- 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Huang C, Huang L, Wang Y, et al. Lancet. 2021;397:220–232.
- The role of autoantibodies in the syndromes of orthostatic intolerance: a systematic review. Ruzieh M, Batizy L, Dasa O, Oostra C, Grubb B. Scand Cardiovasc J. 2017;51:243–247.
- Enhanced external counterpulsation as a novel treatment for post-acute COVID-19 sequelae. Dayrit JK, Verduzco-Gutierrez M, Teal A, Shah SA. Cureus. 2021;13:0.
- Autoimmune postural orthostatic tachycardia syndrome. Watari M, Nakane S, Mukaino A, et al. Ann Clin Transl Neurol. 2018;5:486–492.
- Impaired endothelial function in patients with postural tachycardia syndrome. Chopoorian AH, Wahba A, Celedonio J, et al. Hypertension. 2021;77:1001–1009.
- Enhanced external counterpulsation improves peripheral artery flow-mediated dilation in patients with chronic angina: a randomized sham-controlled study. Braith RW, Conti CR, Nichols WW, Choi CY, Khuddus MA, Beck DT, Casey DP. Circulation. 2010;122:1612–1620.
- Postural orthostatic tachycardia syndrome: JACC Focus Seminar. Bryarly M, Phillips LT, Fu Q, Vernino S, Levine BD. J Am Coll Cardiol. 2019;73:1207–1228.
Source: PubMed